Monitoring and Population HealthShared Care and High-Risk Medicines

Shared care, understood at a glance.

A specialist starts a high-risk medicine under shared care; Reedley organises the protocol’s monitoring, the responsible clinicians, the latest results and outstanding actions; your team acts.

Illustrative demonstration · intended workflow

Interactive demonstration

Synthetic patient · pause, step and replay at any point

Shared care: oral methotrexate

Synthetic patient

Shared care is a set of named responsibilities and dated evidence. Reedley keeps them in one view; clinicians keep the decisions.

Janet RILEYNHS 999 000 2053Born 24 Jun 1965 · 61 y · Female
Janet RILEY NHS 999 000 2053

Born 24 Jun 1965 · 61 y · Female

Shared care is a set of named responsibilities and dated evidence. Reedley keeps them in one view; clinicians keep the decisions.

Step 1 of 7 · Recorded medicine

  1. Recorded medicine
  2. Monitoring protocol
  3. Who is responsible
  4. Investigations with dates
  5. Outstanding actions
  6. Follow-up
  7. Evidence and audit history
At a glance · who did what, and whenRecord as at 2 Nov 2026, 08:00

Recorded medicine

  • MondayMethotrexate 2.5 mgsix tablets
  • Tuesday: none
  • Wednesday: none
  • ThursdayFolic acid 5 mgone tablet
  • Friday: none
  • Saturday: none
  • Sunday: none
Source passages (2)

Repeat entry

Methotrexate 2.5 mg tablets · Six tablets once weekly on Mondays · Repeat · Review date 31 Oct 2026 · Last issued 26 Oct 2026

Repeat entry

Folic acid 5 mg tablets · One once weekly on Thursdays · Repeat · Last issued 26 Oct 2026

Monitoring protocol

Calder and Northfield ICB (fictional) · Shared care guideline: oral methotrexate for adults with inflammatory arthritis · version 2.1 (synthetic document)

Synthetic document
Source passages (2)

Monitoring once stable

Once stable: full blood count, liver function tests and creatinine or eGFR at least every 12 weeks.

Prescribing

Methotrexate is taken once a week, on the same day each week. Prescribe 2.5 mg tablets only.

Who is responsible

Specialist team

Dr J. KOWALSKI, Consultant Rheumatologist (synthetic)

Assesses, initiates and stabilises; sets the monitoring schedule; reviews at least annually; advises when asked.

Responsibilities · 15 Jan 2026

GP practice

Dr Helen MARSH, GP (synthetic)

Prescribes once stable and accepted; arranges monitoring at the agreed interval; reviews results; contacts the specialist team per the guideline.

Responsibilities · 15 Jan 2026

Admin team

Admin team

Invites and books monitoring blood tests (assigned work item).

Source passages (3)

Responsibilities

Specialist team: assesses, initiates and stabilises treatment, sets the monitoring schedule, reviews the patient at least annually and gives advice when asked. GP practice: prescribes once the patient is stable and the agreement is accepted, arranges monitoring blood tests at the agreed interval, reviews results and contacts the specialist team as set out in section 5.

Shared care request · Dr J. KOWALSKI, Consultant Rheumatologist (synthetic)

Mrs Riley is stable on methotrexate 15 mg once weekly (six 2.5 mg tablets every Monday) with folic acid 5 mg once weekly on Thursdays. Please could you take over prescribing and monitoring under the shared care guideline.

Shared care accepted · Dr Helen MARSH, GP (synthetic)

Shared care for methotrexate accepted. Specialist team informed. (Simulated)

Investigations with dates

Each monitoring set with its sample, received and reviewed dates.

Source passages (4)

Results received 7 Jul 2026 15:30

Results received 7 Jul 2026 15:30 · Sample taken 7 Jul 2026 08:50 · Full blood count, liver function tests, creatinine and eGFR reported · No laboratory flags

Result review · Dr Helen MARSH, GP (synthetic)

Methotrexate monitoring results of 7 Jul 2026 reviewed and filed. (Simulated)

Results received 29 Sep 2026 14:05

Results received 29 Sep 2026 14:05 · Sample taken 29 Sep 2026 08:40 · Full blood count, liver function tests, creatinine and eGFR reported · No laboratory flags

Result review · Dr Helen MARSH, GP (synthetic)

Methotrexate monitoring results of 29 Sep 2026 reviewed and filed. (Simulated)

Outstanding actions

  • AssignedNext methotrexate monitoring bloods: FBC, LFT, creatinine or eGFR

    Owner Admin teamDue by 22 Dec 2026

    The synthetic guideline sets at least every 12 weeks once stable; the last sample was taken on 29 Sep 2026 (results received the same day), so the next is due by 22 Dec 2026.

    Monitoring once stable · 15 Jan 2026Results received 29 Sep 2026 14:05

    Closes only with Results received in the record, then a review by a named clinician. A booking or request does not verify.

  • IdentifiedRepeat review date passed for methotrexate (31 Oct 2026)

    Owner Prescriber

    The repeat entry carries a review date of 31 Oct 2026.

    Repeat entry · 26 Oct 2026

    Closes only with A review of the repeat item recorded by a named prescriber.

Follow-up

Specialist review in 12 months, arranged by the specialist team.

Source passage

Annual review · Dr J. KOWALSKI, Consultant Rheumatologist (synthetic)

Her arthritis remains well controlled. Continue methotrexate 15 mg once weekly and folic acid 5 mg once weekly. Continue monitoring under the shared care guideline. We will see her again in 12 months.

Evidence and audit history

The agreement entries and every event since 1 Jul 2026, each with its source; nothing closes without evidence.

  1. 20 Feb 2026Shared care request received from rheumatologyShared care request · 20 Feb 2026
  2. 3 Mar 2026, 12:15Shared care accepted by Dr H. MARSH (synthetic)Shared care accepted · 3 Mar 2026
  3. 7 Jul 2026, 15:30Monitoring results receivedResults received 7 Jul 2026 15:30
  4. 8 Jul 2026, 09:40Reviewed and filed by Dr H. MARSH (synthetic)Result review · 8 Jul 2026
  5. 29 Sep 2026, 14:05Monitoring results receivedResults received 29 Sep 2026 14:05
  6. 30 Sep 2026, 10:05Reviewed and filed by Dr H. MARSH (synthetic)Result review · 30 Sep 2026
  7. 15 Oct 2026Annual specialist review letter: continue; next review in 12 monthsAnnual review · 15 Oct 2026
  8. 26 Oct 2026Repeat issued (issued is not taken)Repeat entry · 26 Oct 2026
  9. 2 Nov 2026, 08:00Reedley: next bloods item identified and assigned to the admin team; repeat review date item identifiedReedley’s own record

Synthetic demonstration · fictional patient, clinicians and organisations · NHS number in the 999 test range · the ICB guideline is a synthetic document · Not connected to any clinical system · Nothing is written to a medication record

Illustrative demonstration · intended workflow · Scripted reconstruction: the development build itself is not running on this page.

  • Who is responsible, for what, under which protocol.
  • Monitoring due, results received and actions still outstanding, side by side.
  • Evidence and audit history kept with every step.

From what arrives to what you decide

  1. What entersA specialist starts a high-risk medicine under shared care
  2. What Reedley preparesProtocol monitoring, responsibilities, latest results and outstanding actions together
  3. What the clinician decidesYour team acts

What it does not do · what exists today

  • Reedley does not decide what a protocol requires: shared-care protocols vary between ICBs and would be configured locally.
  • Monitoring and follow-up for high-risk medicines exist in the development build on synthetic data; the shared-care register itself is the intended workflow. Those monitoring rules are drafts with no clinical owner and differ from national guidance.
  • Not yet in Reedley’s intended-purpose register: shown to explore the workflow, not as committed product scope.

Every patient shown is synthetic. No integration with a clinical system is claimed, and no clinician has yet used Reedley in practice. Safety and governance

See it with your own work in mind.

Tell us your role and the workflows you care about, and we will walk you through them on synthetic data.